A New Drug Application for the EE and NERD indications for tegoprazan will be submitted in the fourth quarter of 2025. Topline data were announced from the maintenance phase of a phase 3 trial ...

The phase 2b REZOLVE-AD trial enrolled 393 adults with moderate-to-severe atopic dermatitis across approximately 110 global sites, randomizing them to three subcutaneous doses of ...

MIAMI, FL, June 24, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network meta-analysis comparing biologics and small molecules. Mirikizumab ...

Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of VK2735, the company's dual agonist of the GLP-1 and GIP receptors. VKTX is ...

Lian indicated the oral VK2735 program is expected to advance into Phase III for obesity, with initiation targeted for the third quarter of 2026. "We currently expect to initiate this program in the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The combination of pembrolizumab and maintenance ...

The USS Dwight D. Eisenhower arrived at Norfolk Naval Shipyard on Jan. 8 for a scheduled Planned Incremental Availability period (PIA) — maintenance, repairs and modernization — after completing a ...

--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; ...